Eight months later he presented with nephrotic-range proteinuria (serum albumin 26 mg/dl, urine protein 14 g/l) secondary to histologically proven membranous glomerulonephritis, in association with fever, systemic upset and elevated inflammatory markers. Serology for hepatitis B, C and syphilis was negative and tenofovir was switched to abacavir. A repeat groin lymph node biopsy revealed Castleman's disease (Fig. 1B) , and quantitative polymerase chain reaction (qPCR) for human herpes virus 8 (HHV8) DNA was 47,000 copies/ml. He was treated initially with valganciclovir 900mg b.d. for 3 months with minimal impact on HHV8 replication, and rituximab (750mg weekly for one month then monthly for 3 months) was introduced.
There was a clinical response with resolution of proteinuria and reduction of lymphadenopathy, however HHV8 replication, anaemia and elevated C-reactive (Fig. 1D ).
This case neatly illustrates the spectrum of HHV-8-associated malignancy that manifests in patients with HIV-1, and raises some interesting points regarding diagnosis and management. Surprisingly, this is the first published report of metachronous KS, MCD and PEL in a person living with HIV, although the coexistence of KS and MCD [1] or MCD and PEL [2] is not unusual. These disorders are aetiologically linked to the gamma herpes virus HHV8 (previously known as
Kaposi sarcoma-associated herpesvirus, KSHV). MCD and PEL are associated with lytic replication, higher levels of the virus detected in plasma, and the paracrine effects of oncogenic viral proteins homologous to interleukin-6, Bcl-2 and several others [3] . KS, MCD and PEL occur at considerably higher frequency in patients with HIV-1 although they have an inconsistent relationship with immunosuppression: KS and PEL are associated with low CD4 counts; MCD, which follows a relapsingremitting course with episodes of systemic inflammation, is unrelated to the degree of immunosuppression and often develops following ART initiation [4] . Thus while the incidence of KS in the post-ART era has fallen dramatically, the incidence of MCD is stable or increasing [3] .
Quantification of HHV8 replication by qPCR in plasma or mononuclear cells has an important role in diagnosis, prognosis and monitoring of treatment response in HHV-8-associted malignancies in HIV, particularly MCD. For example, the presence of high plasma HHV8 DNA levels in patients with KS should prompt a diagnostic search for synchronous MCD [5] . HHV-8 DNA > 40,000 copies/ml was associated with risk of death in an HIV-MCD cohort [6] , and a rising HHV8 level appeared to predict the occurrence of symptomatic episodes [7] . The role of HHV8 monitoring in PEL is unclear [3] . As demonstrated here, valganciclovir has only a modest impact on HHV8
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replication kinetics in vivo [3] , and remission rates in MCD are inferior to the anti-CD20 monoclonal antibody (mAb) rituximab [3] -which remains the mainstay of therapy, with 5 year relapse-free survival of 82% (CI 72-92%) [8] . Tocilizumab, an interleukin-6 receptor specific mAb, has shown promise [9, 10] , but no randomised trial evidence is available. An association between MCD and nephrotic syndrome has been reported previously [11] [12] [13] 
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